Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IQV 
IQVIA Holdings Inc (IQV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: IQV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
23 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $189.65
1 Year Target Price $189.65
| 14 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.96% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 28.48B USD | Price to earnings Ratio 22.46 | 1Y Target Price 189.65 |
Price to earnings Ratio 22.46 | 1Y Target Price 189.65 | ||
Volume (30-day avg) 23 | Beta 1.29 | 52 Weeks Range 134.65 - 252.88 | Updated Date 07/2/2025 |
52 Weeks Range 134.65 - 252.88 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.61% | Operating Margin (TTM) 13.71% |
Management Effectiveness
Return on Assets (TTM) 5.3% | Return on Equity (TTM) 21.64% |
Valuation
Trailing PE 22.46 | Forward PE 13.72 | Enterprise Value 40762530000 | Price to Sales(TTM) 1.84 |
Enterprise Value 40762530000 | Price to Sales(TTM) 1.84 | ||
Enterprise Value to Revenue 2.63 | Enterprise Value to EBITDA 11.86 | Shares Outstanding 173000000 | Shares Floating 164478020 |
Shares Outstanding 173000000 | Shares Floating 164478020 | ||
Percent Insiders 0.96 | Percent Institutions 95.59 |
Upturn AI SWOT
IQVIA Holdings Inc
Company Overview
History and Background
IQVIA Holdings Inc. was formed in 2017 through the merger of IMS Health and Quintiles. IMS Health was founded in 1954, while Quintiles was established in 1982. The merger created a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry.
Core Business Areas
- Technology & Analytics Solutions: Provides technology-enabled solutions, including real-world data, advanced analytics, and technology platforms to help clients improve their clinical and commercial performance.
- Research & Development Solutions: Offers contract research services (CRO), including clinical trial management, site management, and central laboratory services to support the development of new therapies.
Leadership and Structure
Ari Bousbib is the Chairman and CEO. The organizational structure is based on business segments with a corporate headquarters providing overall strategic direction and support.
Top Products and Market Share
Key Offerings
- IMS OneKey: A comprehensive database of healthcare professionals and organizations. Market share is estimated at 30% within the healthcare professional data market. Competitors include Veeva Systems (VEEV) and Definitive Healthcare (DH).
- Orchestrated Customer Engagement (OCE): A cloud-based customer relationship management (CRM) platform for the life sciences industry. It's difficult to establish market share of OCE in general with different products, but the total CRM spend in healthcare is very high. The competitors are Veeva Systems (VEEV).
- Clinical Trial Management Systems (CTMS): Software to manage and track clinical trial progress. Market share is estimated to be 15%. Competitors include Veeva Systems (VEEV) and Oracle (ORCL) Health Sciences.
Market Dynamics
Industry Overview
The life sciences industry is experiencing significant growth driven by innovation in drug development, increasing demand for personalized medicine, and expanding healthcare access globally. The pharmaceutical R&D landscape is also increasingly complex.
Positioning
IQVIA is a leader in providing end-to-end solutions to the life sciences industry, with a strong focus on data and analytics. Its competitive advantage lies in its comprehensive data assets and global reach.
Total Addressable Market (TAM)
The total addressable market is expected to be over $100 billion, including the contract research organization market and analytics market. IQVIA is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Large and comprehensive data assets
- Global reach and scale
- Strong technology platform
- End-to-end solutions offering
- Established relationships with pharmaceutical companies
Weaknesses
- High level of debt
- Reliance on the pharmaceutical industry
- Integration challenges following mergers and acquisitions
- Data privacy and security concerns
Opportunities
- Growing demand for real-world data and analytics
- Expansion into emerging markets
- Increasing adoption of cloud-based solutions
- Personalized medicine and targeted therapies
- Strategic acquisitions to expand capabilities
Threats
- Competition from other CROs and technology providers
- Regulatory changes impacting the pharmaceutical industry
- Economic slowdown and reduced pharmaceutical R&D spending
- Cybersecurity threats and data breaches
- Price pressures from healthcare payers
Competitors and Market Share
Key Competitors
- VEEV
- CTLT
- PPD
Competitive Landscape
IQVIA has a strong competitive position due to its large data assets and global reach. However, it faces competition from other CROs and technology providers.
Major Acquisitions
DeepIntent
- Year: 2024
- Acquisition Price (USD millions): 700
- Strategic Rationale: The acquisition of DeepIntent enhances IQVIA's targeted digital advertising capabilities for the healthcare industry.
Datavant
- Year: 2024
- Acquisition Price (USD millions): 1450
- Strategic Rationale: The acquisition of Datavant increased IQVIA's RWD offerings allowing them to access more data to train better AI and Machine learning models.
Growth Trajectory and Initiatives
Historical Growth: IQVIA has experienced significant growth in revenue and earnings over the past five years, driven by organic growth and acquisitions.
Future Projections: Analysts project continued revenue growth in the coming years, driven by increasing demand for data and analytics solutions. EPS is also expected to increase as the company improves its efficiency.
Recent Initiatives: IQVIA has recently focused on expanding its real-world data capabilities, investing in artificial intelligence and machine learning, and strengthening its partnerships with pharmaceutical companies.
Summary
IQVIA is a strong player in the healthcare analytics and CRO space, benefiting from its vast data assets and global presence. Its revenue has grown consistently. However, the company has to carefully watch its debt and competition. Its recent strategic acquisitions should improve long term outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IQVIA Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IQVIA Holdings Inc
Exchange NYSE | Headquaters Durham, NC, United States | ||
IPO Launch date 2013-05-09 | CEO & Chairman Mr. Ari Bousbib | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 89000 | Website https://www.iqvia.com |
Full time employees 89000 | Website https://www.iqvia.com | ||
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.